PDCD1 and neoplasm: Effects of CRISPR/Cas9 to target both HPV and PD-1 in vitro and in vivo models (104) were tested, and results showed that the combination therapy with gRNA-PD-1 and gRNA-HPV16 E6/E7 significantly reduced tumor growth and enhanced survival.